Physician profile
Laura A Hunt
NPI 1780606780
$4,109.52
in general payments reported to CMS, 2019-2025
38 companies · $60.71 in 2025
The $60.71 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,330 · 2020: $672 · 2021: $752 · 2022: $735 · 2023: $561 · 2025: $60.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $538.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $418.89 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $323.10 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $293.67 | 2019-2023 | Mounjaro |
| Astellas Pharma US INC | $236.91 | 2019-2022 | |
| Glaxosmithkline, LLC. | $224.04 | 2019-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $180.96 | 2019-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.16 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $174.94 | 2019-2021 | |
| Pfizer INC. | $151.71 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.72 | 2019-2023 | Xifaxan |
| Amarin Pharma, INC. | $147.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $142.56 | 2019-2023 | |
| Amgen INC. | $127.17 | 2019-2023 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $65.90 | 2020-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.